Leukemia & lymphoma · 2025
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amrein Philip C, Preffer Frederic I, Fell Geoffrey, Attar Eyal C, Narayan Rupa, Blonquist Traci M, Brunner Andrew M, Hobbs Gabriela S, Hock Hanno R, McAfee Steven L, Moran Jenna A, Bergeron Meghan K, Foster Julia E, Bertoli Christina, McGregor Kristin, Connolly Christine, Behnan Tanya T, Som Tina T, Ramos Aura Y, Vartanian Megan K, Lombardi Story Jennifer, Neuberg Donna S, Fathi Amir T
Аннотация
Outcome for acute myeloid leukemia (AML) patients aged >60 years is poor. Targeting the proteasome in AML is attractive, since leukemia stem cells demonstrate sensitivity to proteasome inhibition in preclinical models. Adults >60 years of age with newly diagnosed AML were enrolled. Induction consisted of cytarabine and daunorubicin with ixazomib provided on days 2, 5, 9, and 12. In a second phase, induction was followed by consolidation with cytarabine and ixazomib on days 2, 5, 9, and 12. Among the 39 patients enrolled, there was 1 DLT, grade 4 thrombocytopenia. There were no grade 3 or 4 neurotoxicity events attributable to ixazomib. The composite remission rate (CCR) was 69%. The median OS for the 39 patients was 38.5 months. The highest dose level (3 mg) of ixazomib planned for induction and consolidation in this trial has been reached safely and is the RP2D for both.